| # | Title | Journal | Year | Citations |
|---|
| 1 | Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen | Journal of Clinical Oncology | 2010 | 716 |
| 2 | A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. | Journal of Clinical Pathology | 1995 | 695 |
| 3 | Proliferation Marker Ki-67 in Early Breast Cancer | Journal of Clinical Oncology | 2005 | 688 |
| 4 | Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy | Journal of Clinical Oncology | 2013 | 557 |
| 5 | Mechanisms of tamoxifen resistance | Endocrine-Related Cancer | 2004 | 523 |
| 6 | Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial | Journal of Clinical Oncology | 2008 | 409 |
| 7 | Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer | British Journal of Cancer | 2004 | 351 |
| 8 | Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free Survival | Clinical Cancer Research | 2005 | 269 |
| 9 | Aromatase inhibitors for breast cancer: lessons from the laboratory | Nature Reviews Cancer | 2003 | 268 |
| 10 | The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer | Breast Cancer Research and Treatment | 2009 | 244 |
| 11 | Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer | Clinical Cancer Research | 2008 | 220 |
| 12 | Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer | Cancer Research | 1995 | 219 |
| 13 | An international study to increase concordance in Ki67 scoring | Modern Pathology | 2015 | 195 |
| 14 | Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival | Clinical Cancer Research | 2005 | 195 |
| 15 | Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy | Journal of the National Cancer Institute | 2016 | 165 |
| 16 | Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques | British Journal of Cancer | 2005 | 161 |
| 17 | Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines | Laboratory Investigation | 2008 | 130 |
| 18 | Cyclooxygenase-2 (COX-2), aromatase and breast cancer:a possible role for COX-2 inhibitors in breast cancer chemoprevention | Annals of Oncology | 2002 | 121 |
| 19 | ARIMIDEX™: A new oral, once-a-day aromatase inhibitor | Journal of Steroid Biochemistry and Molecular Biology | 1995 | 118 |
| 20 | Molecular response to aromatase inhibitor treatment in primary breast cancer | Breast Cancer Research | 2007 | 109 |
| 21 | Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy | Breast Cancer Research and Treatment | 1998 | 105 |
| 22 | Assessment of HER2 status in breast cancer | European Journal of Cancer | 2000 | 103 |
| 23 | Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer | Breast Cancer Research and Treatment | 2010 | 98 |
| 24 | Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy | Annals of Oncology | 2015 | 95 |
| 25 | Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women | Journal of Clinical Oncology | 2010 | 94 |
| 26 | The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients | European Journal of Cancer | 1992 | 87 |
| 27 | Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells | Cytometry | 2003 | 87 |
| 28 | International Web-based consultation on priorities for translational breast cancer research | Breast Cancer Research | 2007 | 86 |
| 29 | Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer | Cancer Research | 1995 | 86 |
| 30 | Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration | Lancet, The | 1993 | 81 |
| 31 | A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors | Breast Cancer Research and Treatment | 2013 | 80 |
| 32 | Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen | Journal of Steroid Biochemistry and Molecular Biology | 2003 | 73 |
| 33 | Physical activity and inactivity in relation to sex hormone, prolactin, and insulin-like growth factor concentrations in premenopausal women | Cancer Causes and Control | 2007 | 73 |
| 34 | Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance | Breast Cancer Research and Treatment | 2005 | 70 |
| 35 | The biology of neoadjuvant chemotherapy for breast cancer. | Endocrine-Related Cancer | 2002 | 69 |
| 36 | Endocrine Therapy, New Biologicals, and New Study Designs for Presurgical Studies in Breast Cancer | Journal of the National Cancer Institute Monographs | 2011 | 69 |
| 37 | Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. | Journal of Clinical Pathology | 1994 | 65 |
| 38 | Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer | British Journal of Cancer | 2012 | 64 |
| 39 | The role of caveolin-1 in human breast cancer | Breast Cancer Research and Treatment | 2012 | 63 |
| 40 | Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer | | 1997 | 62 |
| 41 | Genome-Wide Association Study of Circulating Estradiol, Testosterone, and Sex Hormone-Binding Globulin in Postmenopausal Women | PLoS ONE | 2012 | 61 |
| 42 | A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer | Breast Cancer Research and Treatment | 2012 | 57 |
| 43 | Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial | Lancet Oncology, The | 2014 | 56 |
| 44 | Mechanisms of resistance to aromatase inhibitors | Journal of Steroid Biochemistry and Molecular Biology | 2005 | 51 |
| 45 | Second generation aromatase inhibitor ? 4-hydroxyandrostenedione | Breast Cancer Research and Treatment | 1994 | 50 |
| 46 | Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer | Seminars in Oncology | 2003 | 49 |
| 47 | Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens | Breast Cancer Research | 2004 | 49 |
| 48 | Control of aromatase in breast cancer cells and its importance for tumor growth | Journal of Steroid Biochemistry and Molecular Biology | 1993 | 46 |
| 49 | Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer | Breast Cancer Research and Treatment | 1999 | 45 |
| 50 | Clinical studies of apoptosis and proliferation in breast cancer. | Endocrine-Related Cancer | 1999 | 44 |
